Jose Ricardo Soares: Genomic Testing for All Patients Considered for Clopidogrel in UK
Jose Ricardo Soares, Relief Pharmacist at Uniphar Group, reposted from University of Liverpool on LinkedIn:
”Genomic testing for all patients considered for clopidogrel (before therapy starts). UK.
Clopidogrel empirically prescribed by doctors is not working in a staggering 29% of patients – being in those ineffective in prevention of stroke or MI.
Why: being a prodrug it must be activated via CYP 2C19 — patients with loss‑of‑function these CYP variants (intermediate/poor metabolisers) get much less antiplatelet effect and more thrombotic events.
So: the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics issued a guideline that recommends CYP2C19 genotyping for all patients in whom clopidogrel is being considered, “where testing is available”.
My opinion, this means that testing will soonly be available in secondary care units across the UK.
Moreover: the PGx (pharmacogenomics) data is stored as structured data into the shared electronic health record, information readily available to the prescribers (hospital, GP/community systems).
This way it will be a once in a lifetime test.
Looks quite futuristic for a patent-expired medicine.”
Quoting University of Liverpool‘s post:
”NEWS I: New UK guideline for clopidogrel recommends pharmacogenetic testing for all patients before prescription
The UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics, led by the University of Liverpool, has published its first clinical guideline focused on the use of the antiplatelet medication clopidogrel, widely prescribed in the UK to prevent blood clots. Pharmacogenomics looks at how differences in our genes can change the way medicines affect each person.
Find out more here.”
Read the full article here.
Stay updated with Hemostasis Today.
-
Apr 6, 2026, 16:39Dhinesh Selvaraju: FDA Approves Narsoplimab (Yartemlea) as 1st Treatment for TA-TMA in Adults and Children
-
Apr 6, 2026, 16:38Linda Vorberg: A Detailed Analysis on The Usefulness of CT for DL-Based Stroke Lesion Segmentation
-
Apr 6, 2026, 16:37Colleen Hearn: Telestroke Helps Resource-Limited Facilities Gain Access to Unavailable Expertise
-
Apr 6, 2026, 16:37Nicolas Hubacz: AI Maps Neuroplasticity in Stroke Recovery – How the Brain Adapts After Injury
-
Apr 6, 2026, 16:36Cristina de Diego Alonso: Movement Is Not Just an Exercise, It Is The Rhythm of Daily Life
-
Apr 6, 2026, 16:35Charles Okyere Boadu: What Is The Most Likely Cause of Persistent Thrombocytopenia Despite Transfusion?
-
Apr 6, 2026, 16:34Tumor Mutations and VTE Risk – New Insights from a 12,500-Patient Cancer Study – JTH
-
Apr 6, 2026, 16:31Wolfgang Miesbach: New Real-World Data Reveal Ongoing Burden in Moderate-to-Severe Haemophilia A
-
Apr 6, 2026, 16:26Heghine Khachatryan։ Targeting High Risk Antiphospholipid Syndrome in Pregnancy with Hydroxychloroquine